{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:49:19Z","timestamp":1767858559132,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12886-019-1044-y","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T07:03:13Z","timestamp":1548658993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-8225","authenticated-orcid":false,"given":"Patricia J.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Sassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle B.","family":"Titunick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Zagon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13167-016-0065-3","volume":"7","author":"S Hagan","year":"2016","unstructured":"Hagan S, Martin E, Enriquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive, and personalised medicine. EPMA J. 2016;7:15.","journal-title":"EPMA J"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","volume":"5","author":"MA Lemp","year":"2007","unstructured":"Lemp MA, Baudouin C, Baum J. The definition and classification of dry eye disease: report of the definition and classification Subcommittee of the International dry eye Workshop. Ocul Surf. 2007;5:75\u201392.","journal-title":"Ocul Surf"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/ICO.0000000000000163","volume":"33","author":"KA Beckman","year":"2014","unstructured":"Beckman KA. Characterization of dry eye disease in diabetic patients versus nondiabetic patients. Cornea. 2014;33:851\u20134.","journal-title":"Cornea"},{"key":"1044_CR4","unstructured":"American Diabetes Association, \n                    http:\/\/www.diabetes.org\/diabetes-basics\/diabetes-statistics\/\n                    \n                   accessed October 2018."},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ajo.2004.10.022","volume":"139","author":"I Kaiserman","year":"2005","unstructured":"Kaiserman I, Kaiserman N, Nakar S, Vinker S. Dry eye in diabetic patients. Am J Ophthalmol. 2005;139:498\u2013503.","journal-title":"Am J Ophthalmol"},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"ORSF81","DOI":"10.1167\/iovs.13-12979","volume":"54","author":"GA Lutty","year":"2013","unstructured":"Lutty GA. Effects of diabetes on the eye. Invest Ophthalmol Vis Sci. 2013;54:ORSF81\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jdiacomp.2006.05.008","volume":"21","author":"P Cousen","year":"2007","unstructured":"Cousen P, Cackett P, Bennett H, Swa K, Dhillon B. Tear production and corneal sensitivity in diabetes. J Diabetes Complicat. 2007;21:371\u20133.","journal-title":"J Diabetes Complicat"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0161-6420(00)00599-6","volume":"108","author":"M Dogru","year":"2001","unstructured":"Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in non-insulin-dependent diabetes mellitus. Ophthalmology. 2001;108:586\u201392.","journal-title":"Ophthalmology"},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2415-2-4","volume":"2","author":"FH Grus","year":"2002","unstructured":"Grus FH, Sabuncuo P, Dick HB, Augustin AJ, Pfeiffer N. Changes in the tear proteins of diabetic patients. BMC Ophthalmol. 2002;2:4.","journal-title":"BMC Ophthalmol"},{"key":"1044_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40123-015-0038-y","volume":"4","author":"LA Vickers","year":"2015","unstructured":"Vickers LA, Gupta PK. The future of dry eye treatment: a glance into the therapeutic pipeline. Ophthalmol Ther. 2015;4:69\u201378.","journal-title":"Ophthalmol Ther"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/OPTH.S117188","volume":"11","author":"MR Godin","year":"2017","unstructured":"Godin MR, Gupta PK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin Ophthalmol. 2017;11:951\u20137.","journal-title":"Clin Ophthalmol"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/jamainternmed.2017.7904","volume":"178","author":"LM Schwartz","year":"2018","unstructured":"Schwartz LM, Woloshin S. A clear-eyed view of Restasis and chronic dry eye disease. JAMA Intern Med. 2018;178:181\u20133.","journal-title":"JAMA Intern Med"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0006-8993(99)01106-3","volume":"822","author":"IS Zagon","year":"1999","unstructured":"Zagon IS, Sassani JW, McLaughlin PJ. Cellular dynamics of corneal wound re-epithelialization in the rat. I Fate of ocular surface epithelial cells synthesizing DNA prior to wounding. Brain Res. 1999;822:149\u201362.","journal-title":"Brain Res"},{"key":"1044_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0006-8993(99)01722-9","volume":"839","author":"IS Zagon","year":"1999","unstructured":"Zagon IS, Sassani JW, McLaughlin PJ. Cellular dynamics of corneal wound re-epithelialization in the rat. II DNA synthesis in the ocular surface epithelium following wounding. Brain Res. 1999;839:243\u201352.","journal-title":"Brain Res"},{"key":"1044_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/01.ico.0000224646.66472.aa","volume":"25","author":"IS Zagon","year":"2006","unstructured":"Zagon IS, Sassani JW, McLaughlin PJ. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea. 2006;25:821\u20139.","journal-title":"Cornea"},{"key":"1044_CR16","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.2337\/diabetes.51.10.3055","volume":"51","author":"IS Zagon","year":"2002","unstructured":"Zagon IS, Jenkins JB, Sassani JW, Lang CM, McLaughlin PJ. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rats. Diabetes. 2002;51:3062.","journal-title":"Diabetes"},{"key":"1044_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/jop.2006.0111","volume":"23","author":"MS Klocek","year":"2007","unstructured":"Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther. 2007;23:89\u2013102.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1044_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.brainresbull.2009.10.009","volume":"81","author":"IS Zagon","year":"2010","unstructured":"Zagon IS, Sassani JW, Carroll MA, McLaughlin PJ. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Res Bull. 2010;81:248\u201355 PMC2815253.","journal-title":"Brain Res Bull"},{"key":"1044_CR19","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/archophthalmol.2009.270","volume":"127","author":"IS Zagon","year":"2009","unstructured":"Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetic mellitus. Arch Ophthal. 2009;127:1468\u201373.","journal-title":"Arch Ophthal"},{"key":"1044_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/ceo.12144","volume":"42","author":"IS Zagon","year":"2014","unstructured":"Zagon IS, Sassani JW, Immonen JA, McLaughlin PJ. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Clin Exp Ophthalmol. 2014;42:159\u201368.","journal-title":"Clin Exp Ophthalmol"},{"key":"1044_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/jop.2015.0070","volume":"32","author":"D Liang","year":"2016","unstructured":"Liang D, Sassani JW, McLaughlin PJ, Zagon IS. Topical application of naltrexone to the corneal surface of healthy volunteers: a safety and tolerability study. J Ocul Pharmacol Ther. 2016;32:127\u201332.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1044_CR22","unstructured":"Naltrexone for Opioid Addiction \n                    https:\/\/www.addictioncenter.com\/treatment\/medications\/naltrexone\/\n                    \n                   accessed October 2018."},{"key":"1044_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1210\/endo-116-1-328","volume":"116","author":"J Greenberg","year":"1985","unstructured":"Greenberg J, Ellyin F, Pullen G, Ehrenpreis S, Singh SP, Cheng J. Methionine-enkephalin and \u03b2-endorphin levels in brain, pancreas, and adrenals of db\/db mice. Endocrinology. 1985;116:328\u201331.","journal-title":"Endocrinology"},{"key":"1044_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2337\/diab.35.10.1143","volume":"35","author":"K Timmers","year":"1986","unstructured":"Timmers K, Voyles NR, Zalenski C. Altered \u03b2-endorphin, met- and leu-enkephalins, and enkephalin-containing peptides in pancreas and pituitary of genetically obese diabetic (db\/db) mice during development of diabetic syndrome. Diabetes. 1986;35:1143\u201351.","journal-title":"Diabetes"},{"key":"1044_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0026-0495(92)90200-T","volume":"41","author":"F Fallucca","year":"1992","unstructured":"Fallucca F, Tonnarini G, Di Blas\u00e9 N, D\u2019Allessandro M, Negri M. Plasma met-enkephalin in type 1 diabetes. Metabolism. 1992;41:460\u20131.","journal-title":"Metabolism"},{"key":"1044_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S0026-0495(96)90004-9","volume":"45","author":"F Fallucca","year":"1996","unstructured":"Fallucca F, Tonnarini G, Di Blas\u00e9 N, D\u2019Allessandro M, Negri M. Plasma met-enkephalin levels in diabetic patients: influence of autonomic neuropathy. Metabolism. 1996;45:1065\u20138.","journal-title":"Metabolism"},{"key":"1044_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/jop.2006.22.377","volume":"22","author":"IS Zagon","year":"2006","unstructured":"Zagon IS, Klocek MS, Sassani JW, Mauger DT, McLaughlin PJ. Corneal safety of topically applied naltrexone. J Ocul Pharm Ther. 2006;22:377\u201387.","journal-title":"J Ocul Pharm Ther"},{"key":"1044_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ijpharm.2014.10.069","volume":"477","author":"H Abdelkader","year":"2014","unstructured":"Abdelkader H, Pierscionek ARG. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharm. 2014;477:631\u201342.","journal-title":"Int J Pharm"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1044-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T19:06:30Z","timestamp":1580151990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1044-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"28 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the Penn State College of Medicine Institutional Animal Care and Use Committee (IACUC \u2013 protocol 47,625).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. ISZ, PJM, and JWS are named inventors on an issued patent held by Penn State University related to this topic. Ocunova has taken a license on this technology, but the authors have received no royalties or compensation.** Michelle Titunick received her PhD subsequent to the study conclusion and currently is a faculty member at Hackensack-Meridian School of Medicine at Seton Hall University, New Jersey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"35"}}